Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 22Ovarian Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1HR+/HER2- Advanced Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

dalpiciclib 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HR Positive HER2 Negative Advanced Breast Cancer × dalpiciclib × Clear all
NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
120 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡